Penalizing FDA for Expanding Mifepristone Access 1

Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies Appropriations Act, 2024. Good (R-VA) amendment to reduce to $1 the salary of the Director of the Center for Drug Evaluation and Research at the FDA as part of ongoing attempts to limit access to mifepristone by targeting trained experts for their scientific and medical decision making. A vote for reproductive freedom was against the amendment.

This measure negatively impacts reproductive freedom.

September 27, 2023

H.R.4368

Voting Record

State/Territory:

Chamber:

Party:

Votes:

Name	State/Territory	Chamber	Party	District	How they voted yea Vote for/in favor of nay Vote against — Abstained, absent, ineligible, present, resigned or deceased L Leader switched vote to preserve right to file a motion to reconsider S The speaker exercised their discretion not to vote
No results found.